Remember when eyelash extensions seemed like a miracle? When all of your girlfriends HAD TO HAVE the fake lashes that they heard all the celebrities were rocking…

The ones that didn’t fall out for like a whole entire month that cost stupid amounts of money? The ones that you could get around the way…in Queens…from this spot that was totally unlicensed. But, said shady spot in Queens only charged $40 bucks for these super amazing fake lashes, so you were willing to take a chance that you might just go blind if it meant having lashes that would make you the envy of women everywhere? I know you remember that, it happened circa 2002.

Well…that’s about to be history. Eyelash extensions are about to be ‘dated’ and they didn’t even get a full 10 year run as the lash treatment du jour.

There’s a cream that’s about to make lash history…And, *fingers crossed* it’s going to be available next year in the U.S.

Thanks to the lovely Sarah for this article.

Here’s the latest:

Allergan to seek Q3 approval for eyelash extender

Last Updated: 2008-06-04 9:00:46 -0400 (Reuters Health)

BANGALORE (Reuters) – Allergan Inc said on Wednesday it plans to apply to U.S. health regulators for marketing approval for its eyelash extender by the end of the third quarter.

The maker of the wrinkle-filler Botox said it has completed testing of the product, bimatoprost, and saw significant eyelash growth when it was applied directly to the base of eyelashes.

Allergan said it expects bimatoprost to be approved by the U.S. Food and Drug Administration next year.

The Irvine, California-based company is targeting sales of $500 million per year for the product in stimulating eyelash growth. It said the global mascara market is worth $3.7 billion a year, according to data from various agencies.

Allergan said if it wins FDA approval, U.S. purchasers will be able to obtain bimatoprost only by prescription.

(Reporting by Varsha Tickoo)

Copyright © 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.